Phase II Open-Label Study of Weekly Taxoprexin (DHA-paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2019
At a glance
- Drugs DHA-paclitaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors American Regent; Luitpold Pharmaceuticals
- 14 Jan 2009 Actual completion date reported as April 2007 by ClinicalTrials.gov.
- 14 Jan 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 24 Aug 2007 The expected completion date for this trial is now 1 Apr 2007.